These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37538810)

  • 1. Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP).
    Herrington WG; Harper C; Staplin N; Haynes R; Emberson J; Reith C; Hooi LS; Levin A; Wanner C; Baigent C; Landray M;
    Kidney Int Rep; 2023 Aug; 8(8):1489-1495. PubMed ID: 37538810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
    Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
    Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C;
    Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS
    Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.
    Harper C; Mafham M; Herrington W; Staplin N; Stevens W; Wallendszus K; Haynes R; Landray MJ; Parish S; Bowman L; Armitage J
    JAMA Netw Open; 2021 Dec; 4(12):e2139748. PubMed ID: 34962561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet agents for chronic kidney disease.
    Natale P; Palmer SC; Saglimbene VM; Ruospo M; Razavian M; Craig JC; Jardine MJ; Webster AC; Strippoli GF
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD008834. PubMed ID: 35224730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial.
    Wise RA; Anderson JA; Amarenco P; Cowans NJ; Crim C; Denvir MA; Gomez CR; Jones MP; Morris A; Niewoehner D; Yates JC
    Clin Trials; 2020 Aug; 17(4):430-436. PubMed ID: 32441114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
    Gaba P; Bhatt DL; Dagenais GR; Bosch J; Maggioni AP; Widimsky P; Leong D; Fox KAA; Yusuf S; Eikelboom JW;
    JAMA Netw Open; 2022 Nov; 5(11):e2243201. PubMed ID: 36409491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.
    Harper C; Mafham M; Herrington W; Staplin N; Stevens W; Wallendszus K; Haynes R; Landray MJ; Parish S; Bowman L; Armitage J
    Heart; 2023 Sep; 109(19):1467-1472. PubMed ID: 37270201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.
    Reith C; Staplin N; Herrington WG; Stevens W; Emberson J; Haynes R; Mafham M; Armitage J; Cass A; Craig JC; Jiang L; Pedersen T; Baigent C; Landray MJ;
    BMC Nephrol; 2017 May; 18(1):147. PubMed ID: 28460629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we need to adjudicate major clinical events?
    Granger CB; Vogel V; Cummings SR; Held P; Fiedorek F; Lawrence M; Neal B; Reidies H; Santarelli L; Schroyer R; Stockbridge NL; Feng Zhao
    Clin Trials; 2008; 5(1):56-60. PubMed ID: 18283081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
    Herrington W; Emberson J; Staplin N; Blackwell L; Fellström B; Walker R; Levin A; Hooi LS; Massy ZA; Tesar V; Reith C; Haynes R; Baigent C; Landray MJ;
    Clin J Am Soc Nephrol; 2014 May; 9(5):914-9. PubMed ID: 24626433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidants for chronic kidney disease.
    Jun M; Venkataraman V; Razavian M; Cooper B; Zoungas S; Ninomiya T; Webster AC; Perkovic V
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008176. PubMed ID: 23076940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-blockers for suspected or diagnosed acute myocardial infarction.
    Safi S; Sethi NJ; Nielsen EE; Feinberg J; Jakobsen JC; Gluud C
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012484. PubMed ID: 31845756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials.
    Wang R; Kawashima H; Hara H; Gao C; Ono M; Takahashi K; Tu S; Soliman O; Garg S; van Geuns RJ; Tao L; Wijns W; Onuma Y; Serruys PW
    Circ Cardiovasc Qual Outcomes; 2021 Nov; 14(11):e008055. PubMed ID: 34666500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.